<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(1)</volume><submitter>Ramillon J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Taste or smell disorders have been reported as strongly associated with COVID-19 diagnosis. We aimed to identify subject characteristics, symptom associations, and antibody response intensity associated with taste or smell disorders.&lt;h4>Methods&lt;/h4>We used data from SAPRIS, a study based on a consortium of five prospective cohorts gathering 279,478 participants in the French general population. In the analysis, we selected participants who were presumably infected by SARS-CoV-2 during the first epidemic wave.&lt;h4>Results&lt;/h4>The analysis included 3,439 patients with a positive ELISA-Spike. Sex (OR = 1.28 [95% CI 1.05-1.58] for women), smoking (OR = 1.54 [95% CI 1.13-2.07]), consumption of more than 2 drinks of alcohol a day (OR = 1.37 [95% CI 1.06-1.76]) were associated w</pubmed_abstract><journal>BMC infectious diseases</journal><pagination>228</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10103027</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study.</pubmed_title><pmcid>PMC10103027</pmcid><pubmed_authors>Ramillon J</pubmed_authors><pubmed_authors>Belhadji L</pubmed_authors><pubmed_authors>SAPRIS study group</pubmed_authors><pubmed_authors>Hoang L</pubmed_authors><pubmed_authors>Correia E</pubmed_authors><pubmed_authors>Amroun A</pubmed_authors><pubmed_authors>Dorival C</pubmed_authors><pubmed_authors>Zins M</pubmed_authors><pubmed_authors>de Lamballerie X</pubmed_authors><pubmed_authors>Hercberg S</pubmed_authors><pubmed_authors>Jusot F</pubmed_authors><pubmed_authors>Enguix M</pubmed_authors><pubmed_authors>Kab S</pubmed_authors><pubmed_authors>Morel V</pubmed_authors><pubmed_authors>Fourie T</pubmed_authors><pubmed_authors>Bajos N</pubmed_authors><pubmed_authors>Druesne-Pecollo N</pubmed_authors><pubmed_authors>Renuy A</pubmed_authors><pubmed_authors>Goldberg M</pubmed_authors><pubmed_authors>Gagliolo JM</pubmed_authors><pubmed_authors>Dufourg MN</pubmed_authors><pubmed_authors>Lusivika-Nzinga C</pubmed_authors><pubmed_authors>Benhammou V</pubmed_authors><pubmed_authors>Ouili O</pubmed_authors><pubmed_authors>Touvier M</pubmed_authors><pubmed_authors>Esseddik Y</pubmed_authors><pubmed_authors>Lydie N</pubmed_authors><pubmed_authors>Beaudoin JC</pubmed_authors><pubmed_authors>Blanche H</pubmed_authors><pubmed_authors>Deschasaux M</pubmed_authors><pubmed_authors>Gerbouin-Rerolle P</pubmed_authors><pubmed_authors>Pellicer M</pubmed_authors><pubmed_authors>Meyer L</pubmed_authors><pubmed_authors>Rouquette A</pubmed_authors><pubmed_authors>Thierry X</pubmed_authors><pubmed_authors>Deleuze JF</pubmed_authors><pubmed_authors>Seston M</pubmed_authors><pubmed_authors>Robineau O</pubmed_authors><pubmed_authors>Pailhe A</pubmed_authors><pubmed_authors>Esperou H</pubmed_authors><pubmed_authors>Allegre J</pubmed_authors><pubmed_authors>Ritmi A</pubmed_authors><pubmed_authors>Charles MA</pubmed_authors><pubmed_authors>Geay B</pubmed_authors><pubmed_authors>Lordmi E</pubmed_authors><pubmed_authors>Sebaoun JM</pubmed_authors><pubmed_authors>Artaud F</pubmed_authors><pubmed_authors>Goderel I</pubmed_authors><pubmed_authors>Milcent K</pubmed_authors><pubmed_authors>Severi G</pubmed_authors><pubmed_authors>Senina N</pubmed_authors><pubmed_authors>Lai C</pubmed_authors><pubmed_authors>Wiernik E</pubmed_authors><pubmed_authors>de Visme S</pubmed_authors><pubmed_authors>Pannetier G</pubmed_authors><pubmed_authors>Simeon T</pubmed_authors><pubmed_authors>Nicol J</pubmed_authors><pubmed_authors>Barry AA</pubmed_authors><pubmed_authors>Marchand L</pubmed_authors><pubmed_authors>Saba Villarroel PM</pubmed_authors><pubmed_authors>Rahib D</pubmed_authors><pubmed_authors>Priet S</pubmed_authors><pubmed_authors>SAPRIS-SERO study group</pubmed_authors><pubmed_authors>Spire A</pubmed_authors><pubmed_authors>Candea A</pubmed_authors><pubmed_authors>Lapidus N</pubmed_authors><pubmed_authors>Zaros C</pubmed_authors><pubmed_authors>Ninove L</pubmed_authors><pubmed_authors>Ancel PY</pubmed_authors><pubmed_authors>Szabo de Edelenyi F</pubmed_authors><pubmed_authors>Gomes-Rima R</pubmed_authors><pubmed_authors>Martin C</pubmed_authors><pubmed_authors>Couffin-Cadiergues S</pubmed_authors><pubmed_authors>Carrat F</pubmed_authors><pubmed_authors>Gressin L</pubmed_authors><pubmed_authors>Mohamed Ali S</pubmed_authors><pubmed_authors>Laplanche C</pubmed_authors><pubmed_authors>Ribet C</pubmed_authors><pubmed_authors>Ayhan N</pubmed_authors><pubmed_authors>Le-Got S</pubmed_authors><pubmed_authors>Pastorino B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study.</name><description>&lt;h4>Background&lt;/h4>Taste or smell disorders have been reported as strongly associated with COVID-19 diagnosis. We aimed to identify subject characteristics, symptom associations, and antibody response intensity associated with taste or smell disorders.&lt;h4>Methods&lt;/h4>We used data from SAPRIS, a study based on a consortium of five prospective cohorts gathering 279,478 participants in the French general population. In the analysis, we selected participants who were presumably infected by SARS-CoV-2 during the first epidemic wave.&lt;h4>Results&lt;/h4>The analysis included 3,439 patients with a positive ELISA-Spike. Sex (OR = 1.28 [95% CI 1.05-1.58] for women), smoking (OR = 1.54 [95% CI 1.13-2.07]), consumption of more than 2 drinks of alcohol a day (OR = 1.37 [95% CI 1.06-1.76]) were associated w</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-26T06:04:25.102Z</modification><creation>2025-02-19T04:00:23.291Z</creation></dates><accession>S-EPMC10103027</accession><cross_references><pubmed>37060075</pubmed><doi>10.1186/s12879-023-08162-7</doi></cross_references></HashMap>